MX2018013471A - Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor. - Google Patents

Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor.

Info

Publication number
MX2018013471A
MX2018013471A MX2018013471A MX2018013471A MX2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A
Authority
MX
Mexico
Prior art keywords
pain
compounds
subunit
voltage
tetrahydropyrimidodiazepine
Prior art date
Application number
MX2018013471A
Other languages
English (en)
Inventor
Almansa Rosales Carmen
Cuevas Cordobés Félix
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2018013471A publication Critical patent/MX2018013471A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos nuevos de fórmula general (I) que muestran una gran afinidad y actividad respecto a la subunidad a2d de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad a2d-1 de los canales de calcio dependientes de voltaje, o una actividad dual respecto a la subunidad a2d de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad a2d-1 de los canales de calcio dependientes de voltaje, y el transportador de noradrenalina (NET). La invención también se refiere al proceso para la preparación de dichos compuestos, así como también a las composiciones que los comprenden y su uso como medicamentos.
MX2018013471A 2016-05-06 2017-05-05 Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor. MX2018013471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382199 2016-05-06
PCT/EP2017/060780 WO2017191304A1 (en) 2016-05-06 2017-05-05 Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions

Publications (1)

Publication Number Publication Date
MX2018013471A true MX2018013471A (es) 2019-06-06

Family

ID=56024209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013471A MX2018013471A (es) 2016-05-06 2017-05-05 Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor.

Country Status (32)

Country Link
US (1) US10590140B2 (es)
EP (1) EP3452475B1 (es)
JP (1) JP6926197B2 (es)
KR (1) KR20190024876A (es)
CN (1) CN109526220B (es)
AR (1) AR108387A1 (es)
AU (1) AU2017260305B2 (es)
BR (1) BR112018072755A2 (es)
CA (1) CA3023379A1 (es)
CO (1) CO2018012002A2 (es)
CY (1) CY1123231T1 (es)
DK (1) DK3452475T3 (es)
ES (1) ES2789676T3 (es)
HR (1) HRP20200668T1 (es)
HU (1) HUE051829T2 (es)
IL (1) IL262825A (es)
LT (1) LT3452475T (es)
ME (1) ME03726B (es)
MX (1) MX2018013471A (es)
MY (1) MY196791A (es)
PH (1) PH12018502337A1 (es)
PL (1) PL3452475T3 (es)
PT (1) PT3452475T (es)
RS (1) RS60528B1 (es)
RU (1) RU2018141084A (es)
SG (1) SG11201809799WA (es)
SI (1) SI3452475T1 (es)
TN (1) TN2018000372A1 (es)
TW (1) TWI736619B (es)
UA (1) UA123789C2 (es)
WO (1) WO2017191304A1 (es)
ZA (1) ZA201807653B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076904A1 (en) * 2017-10-16 2019-04-25 Esteve Pharmaceuticals, S.A. PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN
SG11202003599UA (en) * 2017-10-27 2020-05-28 Esteve Pharmaceuticals Sa New alcoxyamino derivatives for treating pain and pain related conditions
WO2019110137A1 (en) * 2017-12-04 2019-06-13 Esteve Pharmaceuticals, S.A. O-phenoxy and o-benzyloxypropylamino derivatives having activity against pain
WO2019115008A1 (en) * 2017-12-12 2019-06-20 Esteve Pharmaceuticals, S.A. Dialkylaminoarylpiperidinyl-o-phenoxy and o-benzyloxypropylamino derivatives having multimodal activity against pain
WO2019149919A1 (en) * 2018-02-05 2019-08-08 Esteve Pharmaceuticals, S.A. Aminopropoxypiperidinylamido derivatives having multimodal activity against pain
WO2020089263A1 (en) * 2018-10-31 2020-05-07 Esteve Pharmaceuticals, S.A. Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions
TW202031264A (zh) * 2018-11-02 2020-09-01 西班牙商埃斯特維製藥公司 用於治療疼痛和疼痛相關疾病的新穎烷氧基氨基吡啶衍生物
WO2020089478A1 (en) * 2018-11-02 2020-05-07 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions
US20220204481A1 (en) * 2019-02-28 2022-06-30 Osaka University Protein and/or peptide modification molecule

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9224101A (en) * 2000-09-27 2002-04-08 Ajinomoto Kk Benzodiazepine derivative
CA2488566A1 (en) 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
EP1724264A1 (en) * 2004-03-10 2006-11-22 Ono Pharmaceutical Co., Ltd. Nitriles and medicinal compositions containing the same as the active ingredient
ZA200806871B (en) * 2006-02-14 2009-10-28 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases
TW200914457A (en) 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)

Also Published As

Publication number Publication date
PH12018502337A1 (en) 2019-07-08
US10590140B2 (en) 2020-03-17
KR20190024876A (ko) 2019-03-08
DK3452475T3 (da) 2020-04-27
AR108387A1 (es) 2018-08-15
EP3452475A1 (en) 2019-03-13
RS60528B1 (sr) 2020-08-31
AU2017260305A1 (en) 2018-12-13
HUE051829T2 (hu) 2021-03-29
JP6926197B2 (ja) 2021-08-25
HRP20200668T1 (hr) 2020-10-16
SG11201809799WA (en) 2018-12-28
TWI736619B (zh) 2021-08-21
EP3452475B1 (en) 2020-02-26
LT3452475T (lt) 2020-05-11
ME03726B (me) 2021-01-20
PT3452475T (pt) 2020-05-05
UA123789C2 (uk) 2021-06-02
BR112018072755A2 (pt) 2019-02-19
CY1123231T1 (el) 2021-10-29
TN2018000372A1 (en) 2020-06-15
TW201808955A (zh) 2018-03-16
ES2789676T3 (es) 2020-10-26
SI3452475T1 (sl) 2020-07-31
PL3452475T3 (pl) 2020-08-24
CO2018012002A2 (es) 2019-04-30
IL262825A (en) 2018-12-31
CN109526220B (zh) 2021-12-21
ZA201807653B (en) 2019-06-26
MY196791A (en) 2023-05-03
CA3023379A1 (en) 2017-11-09
CN109526220A (zh) 2019-03-26
RU2018141084A (ru) 2020-06-08
AU2017260305B2 (en) 2021-04-01
RU2018141084A3 (es) 2020-06-11
JP2019515039A (ja) 2019-06-06
WO2017191304A1 (en) 2017-11-09
US20190144455A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
PH12017501921A1 (en) Novel compounds
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019002356A (es) Compuestos de biarilo utiles como inmunomoduladores.
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
IL288278A (en) Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2017014035A (es) Formas solidas novedosas.
MY197440A (en) Heteroamatic compounds as btk inhibitors
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
PH12020550594A1 (en) New alcoxyamino derivatives for treating pain and pain related conditions
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain